ArticleJournal for immunotherapy of cancer2026
LRIG2 suppresses NK cell-induced GSDME-mediated pyroptosis via the LAMP1-STAT3 pathway in glioma.
Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Short-chain fatty acids promote post-myocardial infarction cardiac repair via FFAR2-dependent suppression of osteoclast-like macrophage differentiation.Basic research in cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGliomas are resistant to current therapies, and natural killer (NK) cell-based immunotherapy shows limited efficacy. Gasdermin E (GSDME)-mediated pyroptosis contributes to NK-induced tumor killing, but NK cell dysfunction in the glioma microenvironment remains poorly understood. This study investigates whether leucine-rich repeats and immunoglobulin-like domains 2 (LRIG2) enable glioma cells to evade NK-induced pyroptosis and elucidates the underlying mechanism.
methodsWe used in vitro co-culture systems with glioma cell lines (LN229, HS683, FU) and primary NK cells or NK92-MI cells to assess cytotoxicity, pyroptosis (lactate dehydrogenase release, morphology, GSDME cleavage by western blot), and cytokine release (Cytometric Bead Array). In vivo, orthotopic glioma models in C57BL/6 and RAG1-KO mice received intracranial stimulator of interferon genes agonist diABZI. Mechanistic dissection involved biochemical approaches (co-immunoprecipitation-mass spectrometry and membrane protein extraction), cellular imaging (immunofluorescence), and genetic perturbation via CRISPR-mediated knockdown.
resultsNK cells induced GSDME-dependent pyroptosis in glioma cells in vitro, but this was impaired in vivo due to suppressed NK cytotoxicity. LRIG2 was highly expressed in gliomas; its overexpression inhibited GSDME cleavage, pyroptosis, and glioma cell death, whereas LRIG2 knockdown enhanced these effects. Mechanistically, soluble LRIG2 shed from glioma cells bound to lysosomal-associated membrane protein 1 (LAMP1) on NK cells, upregulating phosphorylated-signal transducer and activator of transcription (p-STAT3) via Janus kinase 1 (JAK1) and reducing granzyme B and perforin release. Disrupting the LRIG2-LAMP1-STAT3 axis by LRIG2 knockdown or STAT3 knockout restored NK cytotoxicity and GSDME cleavage. Combining LRIG2 knockdown with diABZI significantly enhanced NK granzyme B expression and prolonged mouse survival.
conclusionsLRIG2 enables glioma immune evasion by suppressing NK-induced GSDME-mediated pyroptosis via the LAMP1-STAT3 pathway. Targeting this axis represents a promising strategy to enhance NK cell-based immunotherapy for gliomas, positioning LRIG2 as a potential biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.